Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.55 |
| ▸ | GLA | P06280 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410900 | 0.83 | POLB (0.65) | KDM4EGLAHPGDALDH1A1MAPT | |
| SCHEMBL17774411 | 0.81 | KDM4E (0.69) | KDM4EGLAHPGDALDH1A1MAPT | |
| SCHEMBL17774416 | 0.81 | KDM4E (0.68) | KDM4EGLAHPGDALDH1A1MAPT | |
| SCHEMBL17774414 | 0.80 | KDM4E (0.67) | KDM4EGLAHPGDALDH1A1MAPT | |
| SCHEMBL13065924 | 0.78 | KMT2A (0.63) | KDM4EGLAHPGDALDH1A1MAPT | |
| SCHEMBL16410991 | 0.77 | KDM4E (0.84) | KDM4EGLAHPGDALDH1A1MAPT | |
| SCHEMBL17779067 | 0.72 | KDM4E (0.53) | KDM4EHPGDALDH1A1MAPTMEN1 | |
| SCHEMBL17774410 | 0.71 | KDM4E (0.70) | KDM4EGLAHPGDALDH1A1MAPT | |
| SCHEMBL7455522 | 0.70 | KDM4E (0.62) | KDM4EGLAHPGDALDH1A1MAPT | |
| SCHEMBL16410921 | 0.70 | KDM4E (0.50) | KDM4EGLAHPGDALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624211-B2 | Anti-cancer compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160145250-A1 | ANTI-CANCER COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2015010032-A1 | ANTI-CANCER COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145250-A1 | ANTI-CANCER COMPOUNDS | SKP2, TP53, TEAD2 | KDM4E 472/4885GLA 1894/4885HPGD 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.